Oruka Therapeutics, Inc. — Form 8-K
Filed August 24, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Oruka Therapeutics hired Todd Edwards as Chief Commercial Officer effective August 24, 2026, with a $525,000 annual base salary, $200,000 signing bonus, 40% annual bonus target, 20,000 stock options, and 100,000 RSUs. The equity vests over 4 years (options) and ~4 years (RSUs). Outside a change-in-control, Edwards receives 12 months severance if terminated without cause; within 60 days of a change-in-control, he receives 1.0x base salary plus target bonus (~$735,000) plus full equity acceleration.
Why this rating
Executive hire is routine. Total year-one cash cost (~$725K base+bonus) is ~0.2% of $371.5M market cap; equity grants are non-dilutive disclosure only. No material business impact.
See more from August 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.